Introduction

Human immunodeficiency virus (HIV) infected individuals with lipodystrophy may benefit from using a synthetic growth hormone-releasing hormone analog known as tesamorelin. There have been no reports of elevated serum aminotransferase levels or incidences of clinically apparent acute liver damage while using Tesamorelin peptide for sale, administered subcutaneously.

Background

Growth hormone-releasing hormone (GHRH) analog Tesamorelin is a synthetic 44-amino acid polypeptide analog (GHRH). The N terminal part of the molecule has been changed to increase its stability and pharmacokinetics compared to native GHRH. There are GHRH receptors in the pituitary gland that Tesamorelin activates. This process results in the creation and secretion of growth hormone that operates on many cells in the body, including the hepatocytes, increasing insulin-like growth factor-1 (IGF-1). Many of the actions of growth hormone in the liver are mediated by IGF-1, which includes growth, suppression of programmed cell death, glucose updating, and lipolysis in the liver. Patients with obesity, diabetes, and lipodystrophy, in particular, have lower than average amounts of IGF-1 in their blood. Patients with HIV-related lipodystrophy were given tesamorelin, which was proven to reduce visceral adiposity and improve their overall health. Tesamorelin was licensed for use in the United States as a treatment to decrease extra abdomen fat in HIV-infected individuals with antiviral medication-related lipodystrophy in 2010. Insulin resistance, obesity, and nonalcoholic fatty liver disease are all potential targets for tesamorelin treatment. Tesamorelin is available in solution in 1 mg/mL vials under the trade name Egrifta. Subcutaneous injections of 2 mg daily are advised. Injection site responses, itching, and other side effects are rare but possible. Tesamorelin elevates IGF-1 levels, and monitoring for rises during treatment is suggested.

There are several advantages to Tesamorelin’s growth hormone-stimulating properties. Enhanced calcium retention, accelerated protein synthesis and muscle development, and increased fat breakdown are part of this process. In a 2017 clinical experiment, Tesamorelin was proven to decrease visceral fat, the fat that surrounds the internal organs. Visceral fat is a significant contributor to the current epidemic of adult obesity in the abdominal region.

As it turns out, research shows that Tesamorelin may boost one’s metabolism. A 2014 research found that mitochondrial activity improved even after only 12 months of therapy. There are two types of mitochondria: those that provide the energy our cells need and those that don’t.

Tesamorelin’s safety has been carefully researched. Tesamorelin was well tolerated and had no significant side effects even when given for prolonged periods in two trials conducted in 2010 and 2017. (e.g., 12 weeks).

IGF-1 levels may also be affected by Tesamorelin. Obese, diabetic, and HIV-positive individuals with a lot of visceral fat had decreased levels of these markers. In patients, tesamorelin can increase IGF-1. Using this medication has the following advantages:

• Loss of weight from the abdomen
• Producing more Human Growth Hormone 
• The ability to think more clearly
• Metabolism may be improved
• There are fewer adverse effects than other substances.

Adverse Reactions to Tesamorelin

Patients who use tesamorelin may have adverse effects due to the medication’s use. When using tesamorelin, you should be aware of specific, frequent adverse effects. Effects That Often Occur:

• Moving is a challenge 
• Muscle spasms or aches
• Discomfort in the thighs or biceps
• A stiffness in one or more joints
• Aches and cramps in the muscles
• Injection-site symptoms such as bleeding, edema, pain, and sensitivity.